The metal(II) complexes were synthesized by addition of corresponding MCl2 (M = Mn2+, Ni2+, Cu2+
and Zn2+) with 1,2-bis(1H-pyrrol-2-ylmethylene)diazane in methanol. The ligand acts as a bidentate
as confirmed from the mass, IR, UV, NMR and EPR spectral studies. The Schiff base ligand forms
hexa-coordinated complexes having octahedral geometry for Mn(II), Ni(II), Zn(II) and Cu(II)
complexes. The metal complexes showed an excellent antimicrobial activity spectrum in vitro against
both Gram-negative (Klebsiella pneumoniae and Acinetobacter baumannii), Gram-positive
(Staphylococcus aureus and Enterococcus faecalis) and human pathogenic bacteria isolates. To find
the binding affinity with protein BSA kinase, for that molecular docking studies were also carried for
all the four synthesized metal(II) complexes. The anticancer activity of the synthesized metal(II)
complexes was also screened against the three human tumor cell lines MCF7 human breast
adenocarcinoma cell line, CaSki human caucasian cervical epidermoid carcinoma and HCT116 human
colon cancer cell lines. The present study showed that Zn(II) complex showed potent inhibition by the
ratio of 80% as compared to the inhibition in the normal cells (L-6).